WGS Q2 2024 Earnings — GeneDx Holdings Corp. Revenue & Financial Results | Market Cap Arena

WGSGeneDx Holdings Corp.

$3B

Q2 2024 Earnings

Healthcare Medical - Healthcare Information Services

Income Statement

Revenue

$71M+44.8% YoY

Gross Profit

$43M60.9% margin

Operating Income

-$11M-15.0% margin

Net Income

-$29M-41.4% margin

EPS (Diluted)

$-1.10

QoQ Revenue Growth

+13.0%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$6M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$389M

Total Liabilities

$195M

Stockholders' Equity

$194M

Cash & Equivalents

$56M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$49M	+44.8%
Gross Profit	$43M	$19M	+129.0%
Operating Income	-$11M	-$52M	+79.5%
Net Income	-$29M	-$47M	+37.6%

Revenue Segments

Diagnostic Test

$69M50%

Diagnostic Test, Third Party Insurance

$52M37%

Diagnostic Test, Institutional Customers

$17M12%

Product and Service, Other

$1M1%

Diagnostic Test, Self Pay

$692,0000%